for people ages 1 month to 17 years (full criteria)
at Los Angeles, California
study start
estimated completion
Principal Investigator
by Jaime Deville



This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma for pediatric patients with underlying medical conditions (cardiovascular disease, lung disease, immunosuppression) who are either infected with SARS-CoV-2 or who have had a high-risk exposure. Study participants will be transfused once with compatible convalescent plasma obtained from an individual who has recovered from documented infection with SARS-CoV-2. Safety information and pharmacokinetic data will be collected.

Official Title

Phase I Study of the Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2


Corona Virus Infection, Coronavirus Infections, anti-SARS-CoV-2 human convalescent plasma


You can join if…

Open to people ages 1 month to 17 years

  • Age ≥ 1 month and < 18 years at the time of consent.
  • Determined to be at high-risk for severe SARS-CoV-2 disease based on the American Academy of Pediatrics definition of immunocompromised children and reported high-risk pediatric subpopulations. These include the following groups: immunocompromised, hemodynamically significant cardiac disease (e.g. congenital heart disease), lung disease with chronic respiratory failure, infant, i.e. child ≤1 year old.
  • Confirmed SARS-CoV-2 infection OR high-risk exposure as defined:
    • Confirmed infection: Child who tested positive for COVID-19 and is no more than 96 hours after onset of symptoms (and within 120 hours at the time of receipt of study plasma).
    • High-risk exposure: Susceptible child who was not previously infected or otherwise immune to SARS-CoV-2 and exposed within 96 hours prior to enrollment (and within 120 hours at the time of receipt of study plasma). Both criteria below should be met:
      1. A household member or daycare center (same room) exposure to a person with confirmed SARS-CoV-2 OR with clinically compatible disease in areas with widespread ongoing transmission
      2. Negative for SARS-CoV-2 (nasopharyngeal or oropharyngeal swab)
  • For females of reproductive potential (defined as having experienced menarche), not pregnant based on testing performed at screening.
  • Parent or legal guardian able and willing to provide signed parent permission.

You CAN'T join if...

  • History of severe reactions (e.g. anaphylaxis) to transfusion of blood products. Individuals with minor reactions such as fever, itching, chills, etc. that resolve spontaneously or respond to pre-medications, and that do not represent more significant allergic reactions, will not be excluded.
  • For females, breastfeeding, or planning to become pregnant/breastfeed during the study period.
  • Participant is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate outside the greater Los Angeles area during the study.
  • Any condition that would, in the opinion of the principal investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol.


  • University of California, Los Angeles (UCLA)
    Los Angeles California 90095 United States

Lead Scientist at UCLA

  • Jaime Deville
    HS Clinical Professor, Pediatrics, Medicine. Authored (or co-authored) 52 research publications


not yet accepting patients
Start Date
Completion Date
University of California, Los Angeles
Phase 1 COVID-19 Research Study
Study Type
Expecting 30 study participants
Last Updated